David Price

Aug 16, 2024 | dovepress.com | Mark Rolfe |Christopher C Winchester |Alison Chisholm |David Price

Back to Journals » Pragmatic and Observational Research » Volume 15 Authors Rolfe MJ, Winchester CC , Chisholm A, Price DB Received 16 August 2024 Accepted for publication 19 September 2024 Published 15 October 2024 Volume 2024:15 Pages 201—207 DOI https://doi.org/10.2147/POR.S478163 Checked for plagiarism Yes Editor who approved publication: Professor Amanda Lee Mark J Rolfe,1 Christopher C Winchester,1,2 Alison Chisholm,1 David B Price3,4 1Oxford PharmaGenesis, Oxford, UK; 2Green Templeton...

Nov 1, 2023 | openres.ersjournals.com | Juby Jacob-Nara |Christian Domingo |Klaus F Rabe |David Price

IntroductionOral corticosteroids (OCS) are commonly used for asthma management, particularly in patients with severe or uncontrolled disease [1]. However, OCS use is associated with increased risk of both acute adverse events and chronic adverse effects, including metabolic, bone- and muscle-related, cardiovascular and psychiatric complications [2, 3].